Hanmi Pharm announced a clinical case of patients that obtained meaningful results by administering HM43239, which is being developed as an innovative drug for treating acute myeloid leukemia (AML) at the American Society of Hematology (ASH).
HM43239 is an innovative new drug candidate that is expected to present a new paradigm for AML treatment through synergies that double-suppress FMS-like tyrosine kinase 3 ITD and TKD that cause AML and SYK.
At the conference, Hanmi Pharm selected and announced some cases of patients who participated in the clinical trials in the U.S. and South Korea, which were conducted with Dr. Naval Daver at the MD Anderson Cancer Center.
The first patient was a 67-year-old woman who was given another therapy, Gilteritinib and Azacitidine, but still unresponsive, after Midostaurin was administered for AML treatment.
Complete Remission was confirmed after one cycle (1 month) after administering HM43239 to the patient and after about two cycles (2 months), the Allogenetic Stem Cell Transplant (ASCT) was recovered to a possible condition and was able to receive the transplant.
HM43239 has been designated as a rare drug by the U.S. FDA to treat acute myeloid leukemia and as a rare drug by the Korean Food and Drug Administration.
"HM43239 is a powerful blood cancer treatment that targets mutations commonly expressed in acute myeloid leukemia and can overcome resistance from existing treatments," said Kwon Se-chang, CEO of Hanmi Pharm. "We will do our best to ensure that current clinical trials are carried out smoothly and commercialized as the next-generation treatment in the blood cancer sector."
